{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/bisphosphonates/","result":{"pageContext":{"chapter":{"id":"0d9951b1-3165-5af5-9601-e12d45a17a6c","slug":"bisphosphonates","fullItemName":"Bisphosphonates","depth":2,"htmlHeader":"<!-- begin field c9ba3320-4cf3-46a3-bfa5-c5454f3fea9b --><h2>Bisphosphonates</h2><!-- end field c9ba3320-4cf3-46a3-bfa5-c5454f3fea9b -->","summary":"","htmlStringContent":"<!-- begin item 42506c44-87da-4d8d-a2a6-a141bd8fac41 --><!-- begin field b6e46acc-7a4e-40a2-9cc4-de7872618c75 --><ul><li>Bisphosphonates are inhibitors of bone resorption.</li><li>They increase bone mineral density by altering osteoclast activation and function.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">SIGN, 2015</a>]</p><!-- end field b6e46acc-7a4e-40a2-9cc4-de7872618c75 --><!-- end item 42506c44-87da-4d8d-a2a6-a141bd8fac41 -->","topic":{"id":"9f86812a-068c-512b-a1a4-07fda4301d21","topicId":"a4e2c95c-bf7f-4277-b693-c3b2761380ed","topicName":"Osteoporosis - prevention of fragility fractures","slug":"osteoporosis-prevention-of-fragility-fractures","lastRevised":"Last revised in May 2020","chapters":[{"id":"f651cf3f-ec13-5c52-9121-2dd61c54dc3c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"55fa9b49-e88f-5e9b-8156-01352a4c94b5","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a36d9df6-8dba-581c-9361-7b771a120859","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0562cda5-80f8-5d79-83f3-f1233a8060e3","slug":"changes","fullItemName":"Changes"},{"id":"8adeb7b7-191a-5ba3-96f4-d25461c0b901","slug":"update","fullItemName":"Update"}]},{"id":"753ec6fc-9992-587b-870c-2a54cddd30c8","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"62fbf7e5-b097-5a47-af2f-56553c8b16fb","slug":"goals","fullItemName":"Goals"},{"id":"e2d42919-7f54-594f-bcb8-06f2625a550f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"eca5799e-0969-539e-b27e-e8ed22c5cc54","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"355020b6-9455-5e78-8a1a-172fc947a117","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3c308a4e-8074-5dca-a9bd-a56405a0595f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"745ec600-96ff-5056-8ab4-7ebb02e5286d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4541ac61-d9f8-5c7e-a415-a2f3b57c3f45","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"36908082-d612-5f9e-8dd3-09d9bc87bf79","slug":"definition","fullItemName":"Definition"},{"id":"127d59dc-ce73-51b5-80c0-d57209058280","slug":"causes","fullItemName":"Causes"},{"id":"4349db35-6c86-5ebc-a13f-6a1dce22e466","slug":"complications","fullItemName":"Complications"},{"id":"710ee28b-5971-5b43-ac4e-22ac6fba154d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c62b535b-c8d0-5ce1-93bb-867c8644eb2f","slug":"risk-factors","fullItemName":"Risk factors"}]},{"id":"35af4f9e-0536-527c-8b94-94cd5f1fa796","fullItemName":"Management","slug":"management","subChapters":[{"id":"bf661812-0f6f-57a2-b0ab-530b799fc4c4","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"85598d9c-79e5-5925-8dee-46b4cd8f2170","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"38706564-322f-50d2-a7e2-7fe637b76407","slug":"calcium-colecalciferol-vitamin-d3-preparations","fullItemName":"Calcium and colecalciferol (vitamin D3) preparations"},{"id":"0d9951b1-3165-5af5-9601-e12d45a17a6c","slug":"bisphosphonates","fullItemName":"Bisphosphonates"}]},{"id":"c086cbd6-b967-579e-9768-901abfa8d3ca","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"726389ef-f472-5512-a1bf-bf15159602fd","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f476f450-a081-5a31-a23e-7b837233a18e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"393e0faf-da4e-5bd5-b705-179c32a6c50b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b11023db-83b9-5207-b99c-7917bef26190","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0b683807-10ff-54fc-936a-06d71aa6f8d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fb240203-2f82-5b14-85ec-55933467aceb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"782a2ad0-e9ec-5fc2-b2e1-95ec79f6a2f8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f0656a98-39c4-59de-aebb-3eebb0d8dc40","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"83163424-0d7b-5a98-ac44-ee10975b6831","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8846e4c5-fe0d-4dde-acb7-125f1016c16d --><h3>What are the adverse effects of bisphosphonates?</h3><!-- end field 8846e4c5-fe0d-4dde-acb7-125f1016c16d -->","summary":"","htmlStringContent":"<!-- begin item 7eafb1f2-a494-46ba-8d9a-938634af6a63 --><!-- begin field e2dc86ef-ffa4-4625-bd9d-8e02c07092e2 --><ul><li><strong>Adverse effects of oral bisphosphonates include:</strong><ul><li>Gastrointestinal (most common) — nausea, dyspepsia, mild gastritis, and abdominal pain. They are more likely to occur in the first month of treatment.</li><li>Bone, joint, and/or muscle pain (common).</li><li>Oesophageal reactions (uncommon) — oesophagitis, oesophageal ulcers, oesophageal strictures, and oesophageal erosions.</li><li>Osteonecrosis of the jaw (rare) — an area of exposed or dead bone in the jaw that has lasted for more than 8 weeks.</li><li>Osteonecrosis of the external auditory canal (very rare).</li><li>Atypical stress fractures have been reported (mainly with alendronate). An increased risk cannot be excluded for other bisphosphonates.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Micromedex, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">BNF 70, 2015</a>]</p><!-- end field e2dc86ef-ffa4-4625-bd9d-8e02c07092e2 --><!-- end item 7eafb1f2-a494-46ba-8d9a-938634af6a63 -->","subChapters":[]},{"id":"eb37b125-10be-5f4a-ab19-9d9494abefa9","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6f955d92-07d6-40d5-834b-f7c7e34d49f4 --><h3>What are the key drug interactions with bisphosphonates?</h3><!-- end field 6f955d92-07d6-40d5-834b-f7c7e34d49f4 -->","summary":"","htmlStringContent":"<!-- begin item c33feae7-e9e8-499e-849e-ccf11483ea91 --><!-- begin field 6950087f-1f68-4c6d-9e3f-978aafb9c915 --><ul><li><strong>There are few significant drug interactions, including:</strong><ul><li><strong>Calcium</strong> <strong>supplements </strong><strong>and</strong><strong> antacids</strong> — concurrent use may result in decreased absorption of the bisphosphonate. A minimum of 30 minutes should be left between taking a bisphosphonate and calcium supplements or antacids.</li><li><strong>Food and drink</strong> — reduced absorption of bisphosphonates may occur if they are taken with food and drinks (other than plain water). Coffee and orange juice reduce bioavailability of bisphosphonates by about 60%. A minimum of 30 minutes should be left between taking a bisphosphonate and food or drink.</li><li><strong>Nonsteroidal anti-inflammatory drugs</strong> — some manufacturers of bisphosphonates advise caution if they are used in conjunction with bisphosphonates, due to the increased risk of gastrointestinal irritation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">BNF 70, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Preston, 2015</a>]</p><!-- end field 6950087f-1f68-4c6d-9e3f-978aafb9c915 --><!-- end item c33feae7-e9e8-499e-849e-ccf11483ea91 -->","subChapters":[]},{"id":"f18d0575-0773-5416-9841-8fdcb2ad688f","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9b26a247-575c-4b56-995b-dff405ba5413 --><h3>What are the contraindications and cautions for bisphosphonates?</h3><!-- end field 9b26a247-575c-4b56-995b-dff405ba5413 -->","summary":"","htmlStringContent":"<!-- begin item 509fe531-e9ad-4682-a95d-de6149ca7414 --><!-- begin field 67fa2dbd-763e-4ab6-be5f-a7eebfbcd460 --><ul><li><strong>Do not prescribe a bisphosphonate to:</strong><ul><li>People with hypocalcaemia or other disturbances of bone and mineral metabolism (such as parathyroid dysfunction and hypovitaminosis D) — these should be treated before starting alendronate or risedronate.</li><li>People with severe chronic kidney disease (CKD) — the threshold varies between the different drugs:<ul><li>Alendronate is not recommended if the estimated glomerular filtration rate (eGFR) is less than 35 mL/minute/1.73 m<sup>2</sup>.</li><li>Risedronate is not recommended if the eGFR is less than 30 mL/minute/1.73 m<sup>2</sup>.</li></ul></li><li>People who are unable to stand or sit upright for at least 30 minutes, or if there are any abnormalities of the oesophagus or other conditions which could delay oesophageal emptying (such as stricture or achalasia) — to reduce the risk of oesophageal reactions. </li><li>Pregnant or breastfeeding women — data on pregnancy and breastfeeding are scarce. Oral bisphosphonates are only licensed for use in postmenopausal women.</li></ul></li><li><strong>Prescribe bisphosphonates with caution to: </strong><ul><li>People with upper gastrointestinal (GI) problems, due to the risk of oesophageal reactions. These include:<ul><li>Dysphagia, oesophageal disease, gastritis, duodenitis, and peptic ulceration.</li><li>A recent history (within the past year) of major GI disease (such as peptic ulcer, active GI bleeding, or surgery of the upper GI tract [other than pyloroplasty]).</li><li>Barrett's oesophagus — consider the benefits and risks of treatment on an individual basis.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">ABPI Medicines Compendium, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">ABPI Medicines Compendium, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">Micromedex, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">BNF 70, 2015</a>]</p><!-- end field 67fa2dbd-763e-4ab6-be5f-a7eebfbcd460 --><!-- end item 509fe531-e9ad-4682-a95d-de6149ca7414 -->","subChapters":[]},{"id":"be31fac2-8a6c-5c26-b888-9caa23de63b2","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field a5505884-0b4e-45c9-bd28-6442d431c3bd --><h3>What advice should I give a person taking a bisphosphonate?</h3><!-- end field a5505884-0b4e-45c9-bd28-6442d431c3bd -->","summary":"","htmlStringContent":"<!-- begin item da2db0b7-b8cf-4379-a199-de8cb65607ea --><!-- begin field 32f1678d-90cb-4bf9-a1c4-ad7bb694fb50 --><ul><li><strong>Oral bisphosphonates must only be taken on an empty stomach </strong>as their absorption is affected by food, drink, and other drugs — for more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/prescribing-information/bisphosphonates/#drug-interactions\">Drug interactions</a>.<ul><li><strong>Risedronate </strong>should be taken before breakfast; however, if this is not practical, it can be taken between meals or in the evening at the same time each day, with strict adherence to the following instructions (to ensure that it is taken on an empty stomach):<ul><li>Before breakfast — must be taken at least 30 minutes before the first food, other medicinal product, or drink (other than plain water) of the day.</li><li>Between meals — should be taken at least 2 hours before or at least 2 hours after any food, other medicinal product, or drink (other than plain water).</li><li>In the evening — should be taken at least 2 hours after any food, other medicinal product, or drink (other than plain water).</li></ul></li><li><strong>Alendronate </strong>must be taken at least 30 minutes before the first food, other medicinal product, or drink (other than plain water) of the day.</li></ul></li><li><strong>Also advise that:</strong><ul><li>The tablet must be swallowed whole and taken with a glass of plain water (at least 200 mL); it must not be sucked or chewed because of a potential for oropharyngeal ulceration.</li><li>It should be taken while in an upright position.</li><li>The person must not lie down for at least 30 minutes after taking the medication.</li><li>The medication must not be taken at bedtime or before getting up in the morning.</li><li>Once weekly preparations should be taken on the same day each week.</li></ul></li><li><strong>Give advice on missed doses:</strong><ul><li>For once-daily preparations of alendronate or risedronate, advise the person:<ul><li>To skip the missed dose for that day.</li><li>To continue on the next day as usual.</li><li>Not to take a double dose to make up for the missed dose.</li></ul></li><li>For once-weekly preparations of alendronate or risedronate, advise the person:<ul><li>To take the missed tablet on the day that it is remembered.</li><li>To continue taking one tablet once a week, on the day the tablet is normally taken.</li><li>That two tablets should not be taken on the same day.</li></ul></li></ul></li><li><strong>A</strong><strong>dvise the person to be aware of possible adverse effects of bisphosphonates, including</strong>:<ul><li>Upper gastrointestinal adverse effects, such as dyspepsia or reflux — these are common in the first month of treatment and often improve with continued use.</li><li>Symptoms of atypical fracture, including new onset hip, groin, or thigh pain.  </li><li>Symptoms of osteonecrosis of the jaw, including jaw pain, swelling, and redness.</li></ul></li><li><strong>Advise the person to have a dental check up <em>before </em>starting bone-sparing treatment. </strong></li><li><strong>Advise the person that <em>after starting</em> bone-sparing treatment, they should: </strong><ul><li>Maintain good oral hygiene.</li><li>Attend routine dental check ups. </li><li>Tell their dentist that they are taking bone-sparing medication.</li><li>Report any symptoms of osteonecrosis of the jaw to their dentist.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/references/\">ABPI, 2015</a>]</p><!-- end field 32f1678d-90cb-4bf9-a1c4-ad7bb694fb50 --><!-- end item da2db0b7-b8cf-4379-a199-de8cb65607ea -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}